NEW YORK (Reuters Health) - Drugs used in the hope of slowing multiple sclerosis progression may help some patients, but at a very high cost, according to a study out Wednesday. The medications in ...

Those who prescribe larger amounts of MS drugs were more likely to have received payments, and those who got payments were ...

Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is ...

A person battling multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, but by 2021 that same patient spent $2,378 annually, a new report finds. Out-of-pocket costs ...

HealthDay News — Nearly 80 percent of neurologists prescribing multiple sclerosis (MS) drugs receive payments from industry, according to a study published online Aug. 26 in BMJ Open.

Even women with more severe MS cases are less likely than men to get critical treatments, a new study finds. Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive ...

Many women are diagnosed with multiple sclerosis (MS) at an age when they are considering starting a family. What does the disease and its medication mean for the child? To answer this question, a ...